Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1.

Abstract

Glottic carcinoma is the most common laryngeal cancer. The outcomes for T1 bulky Glottic carcinoma and T2N0 Glottic carcinoma after radiation therapy alone are unsatisfactory. This study was conducted to evaluate the efficacy and safety of unique concurrent chemoradiotherapy regimen using S-1 for early glottic cancer. Concurrent chemoradiotherapy consisted of 60 Gy in 30 fractions with once-daily, orally administered S-1 exclusively within three to six hours prior to each irradiation. Twenty-one consecutive patients treated with this regimen were retrospectively reviewed. Initial complete remission was achieved in all patients without any subsequent local and/or regional recurrences to the last follow-up. The 4-year local control, overall survival, and disease-free survival rates were all 100%. No significant toxicities were observed, except for three cases with Grade 3 acute dermatitis.This regimen is highly effective and well-tolerated, and these results encourage further research to long-term efficacy and functional preservation.

• Authors: Yuuki Takase, Yoshiyuki Itoh, Kazuhiro Ohtakara, Mariko Kawamura, Junji Ito, Yumi Oie, Tamami Ono, Yutaro Sasaki, Ayumi Nishida, Shinji Naganawa
• Journal: Nagoya journal of medical science (Nagoya J Med Sci) Vol. 83 Issue 2 Pg. 251-258 (May 2021) ISSN: 2186-3326 [Electronic] Japan
• PMID: 34239173 (Publication Type: Journal Article)

Topics

• Chemoradiotherapy
• Glottis (pathology)
• Humans
• Laryngeal Neoplasms (drug therapy, radiotherapy)
• Neoplasm Staging
• Retrospective Studies